Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH Highlights
Filter by Topic
ASH 2011 Annual Meeting
ASH 2013 Annual Meeting
ASH 2014 - Castleman's Disease
ASH 2014 - CLL
ASH 2015 - Multiple Myeloma
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
ASH 2015 – Leukemia
ASH 2017
ASH 2017 - Acute Myeloid Leukemia
ASH 2019 Wrap-up
Abexinostat in Patients with NHL and CLL: Results of an Ongoing Phase 2 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Relapsed/Refractory NHL
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Venetoclax (ABT-199/GDC-0199) plus Bendamustine/Rituximab in Relapsed/Refractory NHL: Results of a Dose-Escalation Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Obinutuzumab plus Ibrutinib as Induction and Maintenance Therapy After Bendamustine Debulking in Patients with CLL: Interim Results of a Phase 2 CLL2-BIG Trial
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib versus Chlorambucil in Patients >65 Years with Treatment-Naïve CLL/SLL: Results from the Phase 3 RESONATE-2 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Phase 2 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib versus Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle-Cell Lymphoma (MCL)
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Syk Inhibitor Entospletinib Monotherapy in CLL/SLL: Phase 2 Trial Results
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
,
ASH Highlights
Conference Correspondent
Read Article
Page 9 of 15
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma